期刊文献+

骨代谢调节剂参与骨关节炎的治疗:作用、问题及前景 被引量:3

Bone metabolic modulators for osteoarthritis: curative efficacy, problems and prospects
下载PDF
导出
摘要 背景:骨关节炎是一种骨关节退化性疾病,主要表现为关节软骨退变和软骨下骨硬化,引起患者关节疼痛、功能下降。近年来,骨代谢调节剂对其治疗作用成为研究热点并应用于临床。目的:综述应用骨代谢调节剂对骨关节炎的作用机制和治疗效果。方法:由第一作者在PubM ed和CNKI等数据库中进行文献检索,关键词为"骨关节炎、骨代谢调节剂、骨质疏松、关节、治疗、甲状旁腺激素、降钙素、二膦酸盐、选择性雌激素受体调节剂"及"Osteoporotic,bone metabolic modulators,osteoarthritis,joint,PTH,CT"等,检索时间为2000年1月到2017年6月。广泛查阅国内外有关骨代谢调节剂对骨性关节炎的作用效果及作用机制的有关文献,并进行综述。结果与结论:骨代谢调节剂对骨关节炎关节具有保护作用,能够减缓骨关节炎软骨以及软骨下骨的破坏,稳定关节内环境,减轻骨关节炎样关节退变,阻止骨关节炎关节的破坏。此外,骨代谢调节剂联合非类固醇抗炎药可以减少相关药物的使用量,降低单一用药的不良反应,可能对骨关节炎的治疗具有更好的治疗效果。 BACKGROUND: Osteoarthritis is a degenerative disease of the joints, mainly characterized by degeneration of articular cartilage and subchondral bone sclerosis, resulting in joint pain and decreased function in patients. In recent years, bone metabolism modulators have become a research hotspot and applied in clinic. OBJECTIVE: To review the mechanism and curative efficacy of bone metabolic modulators for osteoarthritis. METHODS: The first author retrieved Pub Med and CNKI databases for relative articles published from January 2000 to June 2017. The keywords were "osteoporotic, bone metabolic modulators, osteoarthritis, joint, PTH, CT" in English and Chinese, respectively. The literature concerning the effects and mechanisms of bone metabolic modulators on osteoarthritis was extensively reviewed and comprehensively analyzed. RESULTS AND CONCLUSION: Bone metabolic modulators have potential protective effects on osteoarthritic joints, preventing cartilage and subchondral bone destruction, reversing osteoarthritis-like joints change and delaying the destruction of osteoarthritic joints. The bone metabolic modulators combined with non-steroidal anti-inflammatory drugs can reduce dosages of related medicines and decrease the side effects caused by single medicine, which may have better therapeutic effects.
作者 孔庆福 勾禹 田发明 张柳 Kong Qing-fu;Gou Yu;Tian Fa-ming;Zhang Liu(Graduate School,North China University of Science and Technology,Tangshan 063000,Hebei Province,China;Hebei Medical University,Shijiazhuang 050017,Hebe Province,China;Medical Research Center of North China University of Science and Technology,Tangshan 063000,Hebei Province,China;Department of Orthopedics,Affiliated Hospital of North China University of Science and Technology,Tangshan 063000,Hebei Province,China)
出处 《中国组织工程研究》 CAS 北大核心 2018年第24期3907-3913,共7页 Chinese Journal of Tissue Engineering Research
基金 国家自然科学基金(31671235) 河北省自然科学基金重点项目(H2016209176) 河北省政府资助临床医学优秀人才培养和基础课题研究项目(361036) 河北省第二批青年拔尖人才支持计划 唐山市科技创新团队培养计划(15130208C)~~
  • 相关文献

参考文献3

二级参考文献28

  • 1National Osteoporosis Foundation Physician' s Guide to Prevention and Treatment of Osteoporosis. Washington, DC: National Osteoporosis Foundation ,2003.
  • 2Rosen CJ, CompstonJE, LianJB. ASBMR Primer on the Metabolic Bone Diseases and Disorders of Mineral Metabolism. 71h? Washington, DC: American Society for Bone and Mineral Research, New York, NY: Wiley InterScience,2008 :259-262.
  • 3Epstein S. Update of current therapeutic options for the treatment of postmenopausal osteoporosis. Clin Ther, 2006,28:151-173.
  • 4Lyritis GP, Georgoulas T, Zafeiris CP. Bone anabolic versus boneanticatabolic treatment of postmenopausal osteoporosis. Ann NY Acad Sci, 2010,1205 :277-283.
  • 5Anastasilakis AD, Goulis DG, Polyzos SA, et al. Head-to-head comparison of risedronate vs. teriparatide on bone turnover markers in women with postmenopausal osteoporosis: a randomised trial. IntJ Clin Pract,2008 ,62 :919-924.
  • 6McClung MR, San MartinJ, Miller PD, et al. Opposite bone remodeling effects of teriparatide and alendronate in increasing bone mass. Arch Intern Med, 2005, 165: 1762-1768.
  • 7Black DM, Greenspan SL, Ensrud KE, et al. The effects of parathyroid hormone and alendronate alone or in combination in postmenopausal osteoporosis. N EnglJ Med, 2003 , 349: 1207- 1215.
  • 8BodyJ J, Gaich GA, Scheele WH, et al. A randomized double?blind trial to compare the efficacy of teriparatide[recombinant human parathyroid hormone (1-34)J with alendronate in postmenopausal women with osteoporosis.J Clin Endocrinol Metab, 2002, 87 :45284535.
  • 9Cosman F, Eriksen EF, Recknor C, et al. Effects of intravenous zoledronic acid plus subcutaneous teriparatide[rhPTH ( 1-34)J in postmenopausal osteoporosis.J Bone Miner Res, 20 II , 26 : 503-511.
  • 10B. L. Langdahl,F. Marin,E. Shane,et al. Teriparatide versus alendronate for treating glucocorticoid-induced osteoporosis: an analysis by gender and menopausal status. Osteoporos Int, 2009 , 20:2095-2104.

共引文献10

同被引文献36

引证文献3

二级引证文献24

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部